PAR10 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF ANTI-TNF-A DRUGS IN PSORIATIC ARTHRITIS  by Eandi, M et al.
provided similar results within acceptable thresholds for
willingness-to-pay (Incremental Cost-Effectiveness Ratio [ICER]
< 35,000, €50,000 or $50,000/QALY). Contrasting results
were, however, found in the etanercept studies. In 3 cases,
etanercept-MTX combination was found to be a cost-effective
strategy compared to other DMARDs (generally MTX alone). In
the other 3 economic evaluations, etanercept (as monotherapy or
in combination with MTX) was not cost-effective compared to
standard DMARDs. CONCLUSION: The review found a pre-
ponderance of cost-effectiveness analyses. Differences in etaner-
cept results appear be due to differences in model structure and
underlying modelling assumptions. This ﬁnding is consistent
with a recent review of inﬂiximab cost-effectiveness analyses.
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OBJECTIVES: The most common treatments for psoriatic
arthritis (PsA) are non steroidal anti-inﬂammatory drugs
(NSAIDs), COX-2 inhibitors, corticosteroids and disease-
modifying antirheumatic drugs (DMARDs). Recently, anti-
TNF-a drugs have been introduced as second line treatments of
PsA. Scope of this study is cost-effectiveness (CEA) and cost-
utility (CUA) analysis of etanercept, inﬂiximab and adalimumab
in the perspective of the Italian National Health System (NHS).
METHODS: A Markov model has been structured in 5 states
describing the clinical condition according to ACR scale: basal
(ACR < 20), ACR20–49, ACR50–69, ACR70–100, failure of
treatment. The transition parameters derived from three different
Phase III pivotal studies of etanercept, inﬂiximab and adali-
mumab versus placebo. The effectiveness was estimated by inte-
grating time with the ACR level (ACRAWs—ACR-Adjusted
Weeks). Utilities were estimated by the correlation of ACR with
HUI-3 and EQ-5D scales. The Markov cycle was 1 week and the
time horizon of the simulation 1 year. RESULTS: One-year treat-
ment cost of etanercept, adalimumab and inﬂiximab for the
Italian NHS are Euro 7,668, Euro 8,354 and Euro 12,631,
respectively. During the same period a gain of 12.67 ACRAWs,
15.11 ACRAWs and 16.20 ACRAWs is obtained with the three
therapies, respectively. C/E ratios of etanercept, adalimumab and
inﬂiximab are 605 Euro/ACRAW, 553 Euro/ACRAW, and 780
Euro/ACRAW, respectively. The treatment with etanercept, adali-
mumab or inﬂiximab induce a gain of 0.1037 QALYs, 0.1241
QALYs and 0.1330 QALYs, respectively, when the utility index is
HUI-3 and a gain of 0.0833 QALYs, 0.0946 QALYs and 0.1020
QALYs, when the utility index is EQ-5D. The C/U ratios of
etanercept are 73,966 Euro/QALY(HUI3) and 92,091 Euro/
QALY(EQ5D), those of adalimumab 67,340 Euro/QALY(HUI3)
and 88,274 Euro/QALY(EQ5D), and those of inﬂiximab 94,940
Euro /QALY(HUI3) and 123,858 Euro/QALY(EQ5D). CON-
CLUSION: The three anti-TNF-a drugs produce different levels
of effectiveness and costs but no strategy is clearly dominated by
any other.
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OBJECTIVES: To determine the cost-effectiveness of introducing
leﬂunomide to standard disease modifying antirheumatic drugs
(DMARD) in rheumatoid arthritis in Poland. METHODS: A
Markov model representing combination of four most popular
DMARD sequences in Poland was developed (based on methotr-
exate, sulphasalazine, chloroquine and cyclosporin). DMARD
sequences including leﬂunomide were compared with those
excluding leﬂunomide. Efﬁcacy, measured according to Ameri-
can College of Rheumatology criteria and Health Assessment
Questionnaire-based utility, was derived from literature review.
Only direct medical costs, measured from the perspective of
National Health Fund were included. Different reimbursement
scenarios were compared. Model time horizon was 25 years.
Cost and beneﬁts were discounted at 5% per year and were
subject to sensitivity analysis (values in Polish zloty (PLN): 1
Euro = 3.8 PLN). RESULTS: Introduction of leﬂunomide into
the standard DMARD sequences resulted in a gain of 0.740
ACR20-, 0.406 ACR50-, 0.211 ACR70 response and 0.171
QALY at an additional cost of 3,164 PLN per patient (corre-
sponding incremental cost-effectiveness ratio (ICER) 18,453
PLN/QALY). In the optimistic and pessimistic scenarios ICER
was estimated at 5,752 PLN/QALY and 37,653 PLN/QALY,
respectively. When only costs were discounted ICER diminished
to 28,714 PLN/QALY and when discounting was not
performed—to 19,558 PLN/QALY. CONCLUSION: Leﬂuno-
mide as an additional option in a DMARD treatment sequences
is cost-effective in rheumatoid arthritis in Poland. Limiting
cyclosporin reimbursement by cheaper leﬂunomide would result
in savings of 3,194 PLN per patient.
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OBJECTIVES: Nonsteroidal anti-inﬂammatory drugs (NSAID)
are frequently used in Czech Republic for pain symptoms asso-
ciated with osteoarthritis (OA). The annual consumption of
NSAID reaches almost 1 billion CZK (36 million €). Non-
selective cyclooxygenase (COX) inhibitors (e.g. diclofenac, ibu-
profen) are mostly prescribed but often cause gastrointestinal
side effects, including life threatening ulceration, perforation or
bleeding (PUB). We assessed direct health care costs of meloxi-
cam (preferential COX-2 inhibitor, daily dose 7.5 mg) versus
piroxicam (20 mg/day) and diclofenac (100 mg/day) based
on two large-scale clinical trials (MELISSA and SELECT).
METHODS: A model based on both studies with meloxicam and
published in literature was used. It included acquisition costs for
medications and costs for management of adverse events (AE).
To identify medical practice in AE management—especially PUB,
a questionnaire was prepared to collect data from gastroenterol-
ogy departments. Eight departments were involved in a retro-
spective data acquisition; these data were translated into
weighted average costs of particular AE treatments. The 2006
prices were used to assess direct medical costs. RESULTS:
Among most costly AEs were gastrointestinal ulceration—mean
costs per patient 160€ (118–225€), bleeding and penetration of
ulcer—934€ (281–1362€) and ulcer perforation 2342€ (1542–
3011€). If gastrointestinal complications of diverse severity were
taken into account, mean costs (per patient treated for 28 days)
for piroxicam were 10.4€, for diclofenac 10.6€ and meloxicam
7.8€. Costs for AE management represented 70–80% of these
costs in non-selective drugs and almost 60% of meloxicam total
costs. CONCLUSION: Management of gastrointestinal AEs gen-
erates a signiﬁcant cost driver of total treatment costs in NSAID
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